ALKS:NASDAQ
Alkermes Plc
$46.18
0.00%
(0.00) 1D
$46.14
arrow_downward
-0.09% (-0.040)todayPre-market
Closed: Nov 19, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Mkt. cap
7.76B
Avg. vol.
1.71M
Volume
0.00
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
Mkt. cap
7.76B
Avg. vol.
1.71M
Volume
0.00
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
News stories
From web sources and news partners
marketscreener.com
·
1 hour ago
Societe Generale sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
42 minutes ago
Mohamed A. El-Erian: S&P 500 may face longest losing streak since 2020 as 10-year Treasury yield falls
Barron's
·
1 hour ago
S&P 500 Futures Decline in Premarket Trading; Lennar, Louisiana-Pacific Lag
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealkermes.com